Tesamorelin
Price range: $49.00 through $99.00 USD
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Supplied for in-vitro laboratory research. Each lot is supplied with its own Certificate of Analysis.
| Form and size | Lyophilized vial |
- Certificate of Analysis for every lot
- HPLC and mass spectrometry testing for every lot
- Lot number on every vial and report
- Protective, discreet packaging
Description
About this material
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). MICROGRAMBIO supplies Tesamorelin as a lyophilized powder in a sealed vial for in-vitro laboratory research. Each lot comes with its own Certificate of Analysis, so you can check the identity and the results for the exact vial you receive.
Research context
In the laboratory literature, Tesamorelin is discussed in work on GHRH receptor signalling and growth-hormone axis pathways in cell-based assays. Researchers use it as a tool to examine these systems in cell-based and other in-vitro models.
Published work comes from many laboratories that use different models, methods and conditions, and a result in one system does not carry over to another. Nothing on this page describes an effect in people or animals. Review the primary literature when you design your own study.
Research focus
- GHRH receptor signalling
- Growth-hormone axis pathways in cell-based assays
- Structure-activity studies of GHRH analogues
Please note
Medicines that contain this substance are regulated in many countries. The material supplied here is a laboratory research reagent, it is not a medicine, and it is not interchangeable with any authorized medicinal product.
What you receive
- A sealed vial of lyophilized powder, in the size you choose above
- A Certificate of Analysis for the lot, with the testing methods and results
- A lot number printed on the vial and on the report
- Protective, discreet packaging
Handling and documentation
Follow the storage instructions on the label and on the report for your lot, together with your laboratory's own procedures. Keep the vial sealed until you need it, and record the lot number, the date you received it and your storage conditions in your laboratory notes. If you need help reading the report, use the guides below or contact us with your order and lot numbers.
Related reading
How to read a peptide Certificate of Analysis · HPLC explained · Storage and handling basics
Specifications
| Size | 5 mg, 10 mg, 15 mg, 20 mg |
|---|---|
| Material type | Peptide |
| Form | Lyophilized powder in a sealed vial |
| Storage | As stated on the label and the report for your lot |
For laboratory research use only. Not for human or animal consumption.
Key features
- Certificate of Analysis supplied for every lot
- Testing methods and results listed on the lot report
- Lot number printed on the vial and on the report
- Supplied as a sealed lyophilized vial
- Four vial sizes: 5, 10, 15 and 20 mg
- Protective, discreet packaging
- For laboratory research use only
How this lot of Tesamorelin is verified
Identity
Mass spectrometry measures the molecular weight of the material so you can confirm the compound in the vial matches the label.
Purity
HPLC shows how much of the sample is the target peptide. The result is written into the report for your lot.
Documentation
The Certificate of Analysis is tied to your lot number. Compare it with the label before you use the material. See our testing process.
Storage and handling
Follow the storage instructions on the label and on the report for your lot, together with your laboratory's own procedures. As general laboratory practice, lyophilized material is kept sealed, dry, protected from light and cold. Record dates and conditions in your laboratory notes.
Questions about Tesamorelin
Is Tesamorelin for human or animal use?
No. Tesamorelin is supplied for laboratory research use only. It is not a drug, is not for human or animal consumption, and is not intended to diagnose, treat, cure or prevent any condition.
Where do I find the lot number and report?
The lot number is printed on the vial label. The Certificate of Analysis for the current lot is linked on this page, and your order confirmation and account show the lot you received.
How is Tesamorelin tested?
Each lot is analysed using HPLC for purity and mass spectrometry for identity, and the results are written into the report for that lot.
Who can buy Tesamorelin?
Qualified researchers and laboratories aged 21 or over. You confirm this when you enter the site and again at checkout.
Where do you ship?
Delivery options and countries are shown at checkout.
More answers on our FAQ page.






Alexander Diaz –
Exceptional dual protocol. Using Tesamorelin in conjunction with CagriSema (Cagrilintide + Semaglutide Combo) maximized total trial efficiency. Tesamorelin was key for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and CagriSema (Cagrilintide + Semaglutide Combo) ensured targeting dual satiety and hunger pathways for potent, comprehensive body weight management. The batch purity report matched our independent verification completely.
Katherine Jackson –
If you are looking to stack complementary peptides, pairing Tesamorelin with Ipamorelin is an absolute winner. Tesamorelin shines for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and when stacked with Ipamorelin, you gain the additional benefit of providing clean, selective growth hormone release without elevating cortisol, prolactin, or appetite. Reconstitution was smooth and instantaneous.
Frank Thomas –
Stacking Tesamorelin and Semaglutide provides a complete, well-rounded protocol. Tesamorelin acts as a baseline by targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, whereas Semaglutide adds synergistic value through effectively reducing appetite, suppressing cravings, and improving glycemic metrics. Both vials dissolved effortlessly without residue.
Joseph Scott –
If you are looking to stack complementary peptides, pairing Tesamorelin with CJC-1295 (No DAC) is an absolute winner. Tesamorelin shines for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and when stacked with CJC-1295 (No DAC), you gain the additional benefit of providing sharp, physiological growth hormone pulses when paired with a growth hormone secretagogue. Reconstitution was smooth and instantaneous.
Jason Williams –
Combining Tesamorelin with CJC-1295 (No DAC) has proven to be one of the most effective protocols in our catalog. Tesamorelin effectively handles targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while CJC-1295 (No DAC) works in tandem to ensure providing sharp, physiological growth hormone pulses when paired with a growth hormone secretagogue. Consistent potency and exceptional quality.
David Roberts –
Stacking Tesamorelin and Sermorelin provides a complete, well-rounded protocol. Tesamorelin acts as a baseline by targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, whereas Sermorelin adds synergistic value through stimulating natural pituitary GH output, enhancing recovery quality, supporting deep sleep, and overall vitality. Both vials dissolved effortlessly without residue.
Lisa Gomez –
Our research team ran a 4-week protocol testing Tesamorelin together with GHRP-6. The results were noticeable from week one: Tesamorelin targeted targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while GHRP-6 enhanced overall effectiveness by strongly stimulating growth hormone release while boosting appetite signaling and digestive motility. Very clean product line and fast shipping.
Eric Morris –
Combining Tesamorelin with Ipamorelin has proven to be one of the most effective protocols in our catalog. Tesamorelin effectively handles targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Ipamorelin works in tandem to ensure providing clean, selective growth hormone release without elevating cortisol, prolactin, or appetite. Consistent potency and exceptional quality.
Karen Phillips –
If you are looking to stack complementary peptides, pairing Tesamorelin with Mazdutide is an absolute winner. Tesamorelin shines for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and when stacked with Mazdutide, you gain the additional benefit of driving significant body weight reduction and optimizing glycemic control markers. Reconstitution was smooth and instantaneous.
Samuel Nelson –
Combining Tesamorelin and GHRP-2 created a remarkable dual-action response. We observed clean activation where Tesamorelin excelled at targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and GHRP-2 stepped in to deliver delivering robust pulsatile growth hormone secretion with a mild appetite stimulation profile. The purity of both compounds was top-notch with zero unexpected side effects.
Charles Cooper –
Exceptional dual protocol. Using Tesamorelin in conjunction with CJC-1295 + Ipamorelin Blend maximized total trial efficiency. Tesamorelin was key for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and CJC-1295 + Ipamorelin Blend ensured maximizing pulsatile growth hormone secretion via dual receptor pathway co-activation. The batch purity report matched our independent verification completely.
David Green –
Combining Tesamorelin and Semaglutide created a remarkable dual-action response. We observed clean activation where Tesamorelin excelled at targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and Semaglutide stepped in to deliver effectively reducing appetite, suppressing cravings, and improving glycemic metrics. The purity of both compounds was top-notch with zero unexpected side effects.
Jessica Gonzalez –
This combination of Tesamorelin and CagriSema (Cagrilintide + Semaglutide Combo) exceeded expectations in our trial run. The inclusion of Tesamorelin was vital for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while CagriSema (Cagrilintide + Semaglutide Combo) amplified overall outcomes by targeting dual satiety and hunger pathways for potent, comprehensive body weight management. Packaging arrived cold and intact, and batch testing confirmed supreme quality.
Anthony Cruz –
Combining Tesamorelin and HGH 191AA created a remarkable dual-action response. We observed clean activation where Tesamorelin excelled at targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and HGH 191AA stepped in to deliver enhancing cellular regeneration, collagen synthesis, lean muscle preservation, and joint resilience. The purity of both compounds was top-notch with zero unexpected side effects.
Amanda Lee –
This combination of Tesamorelin and CJC-1295 + Ipamorelin Blend exceeded expectations in our trial run. The inclusion of Tesamorelin was vital for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while CJC-1295 + Ipamorelin Blend amplified overall outcomes by maximizing pulsatile growth hormone secretion via dual receptor pathway co-activation. Packaging arrived cold and intact, and batch testing confirmed supreme quality.
Maria Davis –
Stacking Tesamorelin and GHRP-2 provides a complete, well-rounded protocol. Tesamorelin acts as a baseline by targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, whereas GHRP-2 adds synergistic value through delivering robust pulsatile growth hormone secretion with a mild appetite stimulation profile. Both vials dissolved effortlessly without residue.
Michelle Campbell –
Combining Tesamorelin and Retatrutide + Cagrilintide Combo created a remarkable dual-action response. We observed clean activation where Tesamorelin excelled at targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and Retatrutide + Cagrilintide Combo stepped in to deliver delivering unmatched weight loss, appetite suppression, and metabolic energy balance. The purity of both compounds was top-notch with zero unexpected side effects.
Richard Ramirez –
Integrating Tesamorelin alongside GHRP-6 in our testing protocol yielded exceptional synergy. Tesamorelin provided reliable support for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while GHRP-6 complemented the protocol perfectly by strongly stimulating growth hormone release while boosting appetite signaling and digestive motility. Both reconstitute cleanly and show outstanding stability. Highly recommended for advanced research.
Joshua Collins –
If you are looking to stack complementary peptides, pairing Tesamorelin with Cagrilintide is an absolute winner. Tesamorelin shines for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and when stacked with Cagrilintide, you gain the additional benefit of promoting early satiety, delaying gastric emptying, and reducing food cravings independently of GLP-1. Reconstitution was smooth and instantaneous.
Stephanie Green –
Our research team ran a 4-week protocol testing Tesamorelin together with Tirzepatide. The results were noticeable from week one: Tesamorelin targeted targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Tirzepatide enhanced overall effectiveness by delivering powerful weight loss, insulin sensitivity improvements, and metabolic regulation. Very clean product line and fast shipping.
Richard King –
Stacking Tesamorelin and Retatrutide + Cagrilintide Combo provides a complete, well-rounded protocol. Tesamorelin acts as a baseline by targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, whereas Retatrutide + Cagrilintide Combo adds synergistic value through delivering unmatched weight loss, appetite suppression, and metabolic energy balance. Both vials dissolved effortlessly without residue.
Anthony Wright –
This combination of Tesamorelin and Survodutide exceeded expectations in our trial run. The inclusion of Tesamorelin was vital for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Survodutide amplified overall outcomes by boosting energy expenditure, promoting liver fat clearance, and controlling caloric intake. Packaging arrived cold and intact, and batch testing confirmed supreme quality.
Christopher King –
Integrating Tesamorelin alongside Liraglutide in our testing protocol yielded exceptional synergy. Tesamorelin provided reliable support for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Liraglutide complemented the protocol perfectly by supporting daily blood glucose stabilization, appetite control, and sustained weight management. Both reconstitute cleanly and show outstanding stability. Highly recommended for advanced research.
Dorothy Torres –
Integrating Tesamorelin alongside Tirzepatide in our testing protocol yielded exceptional synergy. Tesamorelin provided reliable support for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Tirzepatide complemented the protocol perfectly by delivering powerful weight loss, insulin sensitivity improvements, and metabolic regulation. Both reconstitute cleanly and show outstanding stability. Highly recommended for advanced research.
Alexander Martin –
This combination of Tesamorelin and Hexarelin exceeded expectations in our trial run. The inclusion of Tesamorelin was vital for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Hexarelin amplified overall outcomes by inducing rapid growth hormone pulses, supporting cardiac muscle health, and accelerating physical recovery. Packaging arrived cold and intact, and batch testing confirmed supreme quality.
Rebecca Johnson –
Combining Tesamorelin and Dulaglutide created a remarkable dual-action response. We observed clean activation where Tesamorelin excelled at targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and Dulaglutide stepped in to deliver providing long-acting glycemic control, metabolic stability, and appetite reduction. The purity of both compounds was top-notch with zero unexpected side effects.
Jeffrey Mitchell –
Combining Tesamorelin with Cagrilintide has proven to be one of the most effective protocols in our catalog. Tesamorelin effectively handles targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Cagrilintide works in tandem to ensure promoting early satiety, delaying gastric emptying, and reducing food cravings independently of GLP-1. Consistent potency and exceptional quality.
Samantha Gomez –
Combining Tesamorelin with MOTS-c has proven to be one of the most effective protocols in our catalog. Tesamorelin effectively handles targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while MOTS-c works in tandem to ensure promoting AMPK activation, metabolic balance, cellular energy production, and exercise capacity. Consistent potency and exceptional quality.
Larry Nguyen –
Our research team ran a 4-week protocol testing Tesamorelin together with CJC-1295 (With DAC). The results were noticeable from week one: Tesamorelin targeted targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while CJC-1295 (With DAC) enhanced overall effectiveness by sustaining elevated baseline growth hormone and IGF-1 levels over an extended multi-day half-life. Very clean product line and fast shipping.
Rachel Davis –
Exceptional dual protocol. Using Tesamorelin in conjunction with Survodutide maximized total trial efficiency. Tesamorelin was key for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and Survodutide ensured boosting energy expenditure, promoting liver fat clearance, and controlling caloric intake. The batch purity report matched our independent verification completely.
Ronald Perez –
Combining Tesamorelin and Sermorelin created a remarkable dual-action response. We observed clean activation where Tesamorelin excelled at targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and Sermorelin stepped in to deliver stimulating natural pituitary GH output, enhancing recovery quality, supporting deep sleep, and overall vitality. The purity of both compounds was top-notch with zero unexpected side effects.
Cynthia Murphy –
Exceptional dual protocol. Using Tesamorelin in conjunction with Hexarelin maximized total trial efficiency. Tesamorelin was key for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, and Hexarelin ensured inducing rapid growth hormone pulses, supporting cardiac muscle health, and accelerating physical recovery. The batch purity report matched our independent verification completely.
Nicholas Green –
Combining Tesamorelin with Mazdutide has proven to be one of the most effective protocols in our catalog. Tesamorelin effectively handles targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Mazdutide works in tandem to ensure driving significant body weight reduction and optimizing glycemic control markers. Consistent potency and exceptional quality.
Benjamin Jones –
Integrating Tesamorelin alongside CJC-1295 (With DAC) in our testing protocol yielded exceptional synergy. Tesamorelin provided reliable support for targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while CJC-1295 (With DAC) complemented the protocol perfectly by sustaining elevated baseline growth hormone and IGF-1 levels over an extended multi-day half-life. Both reconstitute cleanly and show outstanding stability. Highly recommended for advanced research.
Eric Gutierrez –
Our research team ran a 4-week protocol testing Tesamorelin together with Liraglutide. The results were noticeable from week one: Tesamorelin targeted targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, while Liraglutide enhanced overall effectiveness by supporting daily blood glucose stabilization, appetite control, and sustained weight management. Very clean product line and fast shipping.
Anthony Smith –
Stacking Tesamorelin and Dulaglutide provides a complete, well-rounded protocol. Tesamorelin acts as a baseline by targeting visceral abdominal fat reduction, stimulating endogenous growth hormone release, and elevating IGF-1, whereas Dulaglutide adds synergistic value through providing long-acting glycemic control, metabolic stability, and appetite reduction. Both vials dissolved effortlessly without residue.